Sinocare Medical: The company's stock price has recently recorded a significant cumulative increase, and there may be a risk of a short-term decline due to the rapid rise.

Sinomed announced on the evening of August 15 that the deviation of the closing price of the stock has accumulated to 200% within 30 consecutive trading days, which indicates a serious abnormal volatility in the stock trading. It was verified that the company's daily production and operation are normal, and there have been no major adjustments in the market environment or industry policies. In addition, Sinomed's holding subsidiary, Sinoshine, has independently developed the COMETIU self-expanding intracranial drug-coated stent system and COMEX balloon microcatheter, which have been granted breakthrough medical device designation by the FDA in the United States. However, this does not guarantee that the products will be approved for listing by the FDA in the future. As of August 15, the closing price of the company's stock was 34.57 yuan per share. The recent cumulative increase in the company's stock price has been significant, exceeding the increases of most companies in the same industry and the Shanghai Composite Index, indicating a potential risk of a rapid decline in the short term.